Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

751.45 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
Via The Motley Fool
3 Companies Reporting Remarkable Results: Walmart, Eli Lilly, Cardinal Health
Several companies have stolen the spotlight throughout the earnings period, including Walmart, Cardinal Health, and Eli Lilly. All three posted robust results and upped guidance, as shares of each... 
Via Talk Markets
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks should keep up their winning ways. 
Via The Motley Fool
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future. 
Via The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare... 
Via Benzinga
Eli Lilly Unusual Options Activity For August 15
Via Benzinga
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years
Via Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... 
Via Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
A small telemedicine company just entered the weight loss race. 
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
There are a number of pharmaceutical companies looking to make waves in the weight loss market. 
Via The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
Beyond The Numbers: 25 Analysts Discuss Eli Lilly Stock
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing... 
Via Benzinga
Exposures Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection... 
Via Benzinga
Up 10% in 1 Day, Is It Too Late to Buy Eli Lilly Stock?
How much upside could this juggernaut stock possibly have left? 
Via The Motley Fool
Being Vain Has Its Benefits. Why Eli Lilly And The 'Me-Conomy' Are Here To Stay.
Eli Lilly stock and Novo Nordisk kicked off the vanity trade, but the "me-conomy" trend is extending to other industries as well. 
Via Investor's Business Daily
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Investing based on the segment's long-term prospects is likely to be very lucrative. 
Via The Motley Fool
3 Stocks on the Rise After Stellar Q2 Earnings Results
These three companies are earnings winners with impressive revenue and profit numbers. They will continue to shine throughout 2024. 
Via InvestorPlace
VOO Vs. VTI: Here Are The Key Differences Between Vanguard US Stock Market ETFs Investors Should Know
A look at the differences and past performance of the VOO and VTI ETFs and how they compare to the SPY ETF. 
Via Benzinga
Topics ETFs
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
A company's investments can easily ruin the plans of its competitors. 
Via The Motley Fool
Why Eli Lilly Stock's Big Jump Last Week Could Be Just the Beginning of Another Huge Run
Many more quarters like Lilly's stellar second quarter could be on the way. 
Via The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer risk, particularly for cancers linked to obesity. New research highlights... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Eli Lilly: A Pharmaceutical Juggernaut That Just Crushed Earnings Estimates
Many have said that pharmaceutical companies would be a logical place to invest if the rest of the market began to slow down. They may have been onto something. Eli Lilly & Co. reported Q2 earnings and... 
Via Talk Markets
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.